Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,303 | 3,440 | 6,846 | 7,377 | 9,119 |
| Marketable Securities | N/A | N/A | N/A | N/A | 115 |
| Receivables | N/A | N/A | N/A | 308 | N/A |
| TOTAL | $9,333 | $5,229 | $8,790 | $8,242 | $10,211 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 7,262 | 7,371 | 6,322 | 6,453 | 9,359 |
| TOTAL | $9,176 | $9,285 | $8,236 | $8,367 | $11,273 |
| Total Assets | $18,509 | $14,514 | $17,026 | $16,609 | $21,484 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,779 | 2,426 | 2,624 | 3,902 | 3,764 |
| Accrued Expenses | 2,304 | 1,809 | 888 | 1,171 | 1,504 |
| TOTAL | $4,219 | $4,325 | $3,635 | $5,290 | $5,574 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 6,080 | 6,144 | 5,067 | 4,964 | 4,916 |
| TOTAL | $6,342 | $6,406 | $5,329 | $5,226 | $5,273 |
| Total Liabilities | $10,561 | $10,731 | $8,964 | $10,516 | $10,847 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 9,462 | 9,462 | 6,718 | 6,718 | 4,872 |
| Common Shares | 10 | 7 | 7 | 1 | 5 |
| Retained earnings | -114,188 | -109,715 | -105,290 | -101,147 | -93,728 |
| TOTAL | $7,948 | $3,783 | $8,062 | $6,093 | $10,637 |
| Total Liabilities And Equity | $18,509 | $14,514 | $17,026 | $16,609 | $21,484 |